Home > Osiris Therapeutics Salary

Osiris Therapeutics Salary

  • 85
  • 96
  • 44
Osiris Therapeutics average salary is $41,122, median salary is $41,122 with a salary range from $41,122 to $41,122.
Osiris Therapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Osiris Therapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
41,122
Average
41,122
Median
41,122
High
41,122
Total 1 Osiris Therapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Technical Services Associate 41,122-41,122 Columbia, MD, 21044 2017 Osiris Therapeutics Technical Services Associate Salaries (1)
Osiris Therapeutics Columbia, MD Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Osiris Therapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Osiris Therapeutics Jobs
See more Osiris Therapeutics Jobs»
Search All Jobs

JobCompare – Find open jobs faster
Patents information
Osiris Therapeutics... Information
  • Osiris Therapeutics , Inc.
  • Industry: BioTech/Drugs
  • City: Columbia, MD
  • Osiris Therapeutics, Inc. (Osiris) is a stem cell therapeutic company, focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The Company¡¯s principal biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the only stem cell therapeutic granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Its pipeline of internally developed biologic drug candidates